{
    "Clinical Trial ID": "NCT01171924",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm A: 5 Days/Week Schedule",
        "  CUDC-101: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.",
        "INTERVENTION 2: ",
        "  Arm B: 3 Days/Week Schedule",
        "  CUDC-101: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Subjects with histopathologically confirmed diagnosis of advanced breast, gastric, head and neck, liver and non-small cell lung cancer.",
        "  For subjects with non-small cell lung cancer only:",
        "  Most recent treatment must be erlotinib and subjects must have had a radiographic partial or complete response to treatment as defined by RECIST criteria and should be currently progressing after the documented response.",
        "  A documented mutation in EGFR exons 19 or 21",
        "  Subjects must have no further standard of care options or have refused standard therapy",
        "  Measurable or evaluable disease",
        "  Age  18 years",
        "  ECOG performance < 2",
        "  Life expectancy  3 months",
        "  If female, neither pregnant or lactating",
        "  If of child bearing potential, must use adequate birth control",
        "  Absolute neutrophil count  1,500/\u00b5L; platelets  100,000/\u00b5L;",
        "  Creatinine  1.5x upper limit of normal (ULN) or calculated creatinine clearance  60mL/min/1.73m2",
        "  Total bilirubin  1.5x ULN; AST/ALT  2.5x ULN. In subjects with documented liver metastases, the AST/ALT may be  5x ULN",
        "  Prothrombin time 1.5x ULN, unless receiving therapeutic anticoagulation",
        "  Serum magnesium and potassium within normal limits (may use supplements to achieve normal values)",
        "  Subjects with brain metastases are eligible if controlled on a stable dose  10mg prednisone/day or its equivalent dose of steroids",
        "  Able to render informed consent and to follow protocol requirements.",
        "Exclusion Criteria:",
        "  Anticancer therapy within 4 weeks of study entry.",
        "  Use of investigational agent(s) within 30 days of study entry",
        "  History of cardiac disease with a New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF), myocardial infarction (MI) or unstable angina in the past 6 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment.",
        "  Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Subjects with liver cancer and hepatitis may be eligible."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Adverse Events",
        "  Safety and tolerability will be assessed in the two treatment arms and the incidence of adverse events will be compared.",
        "  Time frame: 12-15 months",
        "Results 1: ",
        "  Arm/Group Title: Arm A: 5 Days/Week Schedule",
        "  Arm/Group Description: CUDC-101: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.",
        "  Overall Number of Participants Analyzed: 23",
        "  Measure Type: Number",
        "  Unit of Measure: participants  23",
        "Results 2: ",
        "  Arm/Group Title: Arm B: 3 Days/Week Schedule",
        "  Arm/Group Description: CUDC-101: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.",
        "  Overall Number of Participants Analyzed: 23",
        "  Measure Type: Number",
        "  Unit of Measure: participants  23"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 12/23 (52.17%)",
        "  Anaemia  0/23 (0.00%)",
        "  Neutropenia  1/23 (4.35%)",
        "  Blood creatinine increased  1/23 (4.35%)",
        "  Supraventricular tacycardia  1/23 (4.35%)",
        "  Abdominal Pain  1/23 (4.35%)",
        "  Oesophageal varices haemorrhage  0/23 (0.00%)",
        "  Pancreatitis  0/23 (0.00%)",
        "  Small intestinal obstruction  0/23 (0.00%)",
        "  Disease progression  5/23 (21.74%)",
        "  Non-cardiac chest pain  1/23 (4.35%)",
        "Adverse Events 2:",
        "  Total: 9/23 (39.13%)",
        "  Anaemia  1/23 (4.35%)",
        "  Neutropenia  0/23 (0.00%)",
        "  Blood creatinine increased  0/23 (0.00%)",
        "  Supraventricular tacycardia  0/23 (0.00%)",
        "  Abdominal Pain  1/23 (4.35%)",
        "  Oesophageal varices haemorrhage  1/23 (4.35%)",
        "  Pancreatitis  1/23 (4.35%)",
        "  Small intestinal obstruction  1/23 (4.35%)",
        "  Disease progression  3/23 (13.04%)",
        "  Non-cardiac chest pain  0/23 (0.00%)"
    ]
}